Keratoconus is a progressive eye disease that can result in significant vision loss, and requires a corneal transplant in 20% of cases. Until recently, there were no therapeutic options to limit the progression of this sight-threatening disease. Corneal collagen cross-linking is an innovative therapy that has transformed the treatment of progressive keratoconus.
Corneal Cross Linking (CXL) is the first and only FDA-approved treatment for keratoconus. This minimally-invasive, out-patient procedure combines the use of Photrexa® specially formulated Vitamin B2 eye drops with UVA light from the KXL® system to create new collagen cross-links and leads to the stiffening of the cornea, preventing your eyesight from getting worse.
The epithelium, or outermost layer of the cornea, is gently and temporarily removed to allow penetration of the medicated eye drops. The cornea is then treated with UVA light using the KXL system. This combination therapy is proven to strengthen corneas that have been weakened by disease.
Yes. The epi-off corneal cross-linking procedure with Photrexa and KXL technology has been rigorously tested in clinical trials. This keratoconus treatment is proven safe, effective, and now, FDA-approved.
Yes. Upon FDA-approval, insurance coverage for corneal cross-linking became widely available. Most medical health insurers now cover this potentially sight-protecting treatment.